Acquisition by Gowen Maxine of 14414 shares of Merus BV at 23.29 subject to Rule 16b-3
MRUS Stock | USD 44.97 0.90 1.96% |
Slightly above 59% of Merus BV's investor base is looking to short. The analysis of the overall investor sentiment regarding Merus BV suggests that many traders are alarmed. Merus BV's investing sentiment can be driven by a variety of factors including economic data, Merus BV's earnings reports, geopolitical events, and overall market trends.
Merus |
Filed transaction by Merus BV Director. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Merus BV's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Merus BV's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Merus BV Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Merus BV can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Merus BV Fundamental Analysis
We analyze Merus BV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Merus BV using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Merus BV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Merus BV is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Merus BV Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Merus BV stock to make a market-neutral strategy. Peer analysis of Merus BV could also be used in its relative valuation, which is a method of valuing Merus BV by comparing valuation metrics with similar companies.
Peers
Merus BV Related Equities
KRON | Kronos Bio | 10.34 | ||||
LRMR | Larimar Therapeutics | 7.44 | ||||
MLYS | Mineralys Therapeutics, | 4.71 | ||||
ADAG | Adagene | 4.05 | ||||
KURA | Kura Oncology | 3.91 | ||||
STRO | Sutro Biopharma | 3.46 | ||||
PCVX | Vaxcyte | 2.77 | ||||
ACRV | Acrivon Therapeutics, | 2.31 | ||||
ANEB | Anebulo Pharmaceuticals | 2.14 | ||||
CRNX | Crinetics Pharmaceuticals | 1.59 | ||||
INBX | Inhibrx | 1.17 | ||||
LYEL | Lyell Immunopharma | 1.10 | ||||
PTGX | Protagonist Therapeutics | 0.27 | ||||
SNDX | Syndax Pharmaceuticals | 0.06 | ||||
ANAB | AnaptysBio | 0.51 | ||||
REPL | Replimune | 2.29 |
Additional Tools for Merus Stock Analysis
When running Merus BV's price analysis, check to measure Merus BV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merus BV is operating at the current time. Most of Merus BV's value examination focuses on studying past and present price action to predict the probability of Merus BV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merus BV's price. Additionally, you may evaluate how the addition of Merus BV to your portfolios can decrease your overall portfolio volatility.